Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (511-520 of 551) with videos related to

Pageof 56
Sort By:
Lancet (London, England)|February 16, 2010
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trialJairam R Lingappa, Jared M Baeten, Anna Wald, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
The Journal of Experimental Medicine|September 5, 2024
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Communications Medicine|April 17, 2026
Viral variant but not host factors associate with SARS-CoV-2 viral kineticsWilliam O Hahn, Leigh H Fisher, Amy Ward, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
Emerging Microbes & Infections|April 7, 2025
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trialsZoe Moodie, Shuying Sue Li, Elena E Giorgi, et al.
Lancet (London, England)|March 20, 2022
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation studyLinda-Gail Bekker, Nigel Garrett, Ameena Goga, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, Hongjun Bai, Allan C deCamp, et al.
Pageof 56

Showing results (511-520 of 551) with videos related to

Sort By:
Pageof 56
Lancet (London, England)|February 16, 2010
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trialJairam R Lingappa, Jared M Baeten, Anna Wald, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
The Journal of Experimental Medicine|September 5, 2024
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Communications Medicine|April 17, 2026
Viral variant but not host factors associate with SARS-CoV-2 viral kineticsWilliam O Hahn, Leigh H Fisher, Amy Ward, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
Emerging Microbes & Infections|April 7, 2025
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trialsZoe Moodie, Shuying Sue Li, Elena E Giorgi, et al.
Lancet (London, England)|March 20, 2022
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation studyLinda-Gail Bekker, Nigel Garrett, Ameena Goga, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, Hongjun Bai, Allan C deCamp, et al.
Pageof 56